Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ocular Therapeut (NQ: OCUL ) 9.840 +0.610 (+6.61%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ocular Therapeut < Previous 1 2 3 4 5 6 7 Next > The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs July 23, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session July 22, 2021 Gainers Xenetic Biosciences (NASDAQ:XBIO... Via Benzinga Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge May 01, 2021 Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... Via Benzinga Exposures Product Safety Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million July 22, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration June 29, 2021 From Ocular Therapeutix, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session June 08, 2021 Gainers Aethlon Medical (NASDAQ:AEMD) sto... Via Benzinga Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences May 26, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update May 05, 2021 From Ocular Therapeutix, Inc. Via Business Wire CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 03, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant May 03, 2021 From Ocular Therapeutix, Inc. Via Business Wire The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues May 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... Via Benzinga 65 Biggest Movers From Yesterday April 30, 2021 Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs. Takung Art Co., Ltd. (... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 29, 2021 Gainers Galera Therapeutics (NASDAQ:GRTX) stock rose 21.78% to $8.05 during Thursday's regular session. As of 12:32 EST, Galera Therapeutics's stock is trading at... Via Benzinga 54 Stocks Moving In Thursday's Mid-Day Session April 29, 2021 Gainers Willamette Valley Vineyards, Inc. (NASDAQ: WVVI) climbed 40.5% to $14.39. Dolphin Entertainment, Inc. (NASDAQ: DLPN) shares gained 23.1% to $14.14. Dolphin Entertainment... Via Benzinga Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting April 29, 2021 From Ocular Therapeutix, Inc. Via Business Wire Ocular Therapeutix™ To Report First Quarter 2021 Financial Results April 28, 2021 From Ocular Therapeutix, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.